CSPC Pharmaceutical Group Limited (HKG:1093)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
8.54
+0.13 (1.55%)
Apr 29, 2026, 9:29 AM HKT
39.77%
Market Cap 96.15B
Revenue (ttm) 28.94B
Net Income (ttm) 4.32B
Shares Out 11.43B
EPS (ttm) 0.38
PE Ratio 22.24
Forward PE 13.13
Dividend 0.29 (3.29%)
Ex-Dividend Date Jun 24, 2026
Volume 112,132,264
Average Volume 87,718,557
Open 8.70
Previous Close 8.41
Day's Range 8.35 - 9.07
52-Week Range 5.34 - 11.63
Beta 0.87
RSI 39.22
Earnings Date May 27, 2026

About CSPC Pharmaceutical Group

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson’s disease; Duomeisu for lymphoma,... [Read more]

Sector Healthcare
Founded 1992
Employees 19,700
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1093
Full Company Profile

Financial Performance

In 2025, CSPC Pharmaceutical Group's revenue was 26.01 billion, a decrease of -10.35% compared to the previous year's 29.01 billion. Earnings were 3.88 billion, a decrease of -10.30%.

Financial numbers in CNY Financial Statements

News

As China’s biotech firms shift gears, can AI floor the accelerator?

A quarter featuring multiple eye-popping deals is no longer unusual for China’s pharmaceutical industry – in fact, it may soon be considered a slow season. In recent months, companies including CSPC P...

10 days ago - South China Morning Post

AstraZeneca Strikes Multibillion-Dollar Obesity Deal With China's CSPC

The agreement to gain rights outside of China to a portfolio of experimental obesity and diabetes drugs could be valued at billions of dollars.

3 months ago - WSJ

China's CSPC Pharmaceutical inks deal with AstraZeneca for weight loss therapy

CSPC Pharmaceutical Group said on Friday it had entered an agreement with UK drugmaker AstraZeneca for the development of innovative long-acting peptide medicines for obesity and weight-related condit...

3 months ago - Reuters